VIENNA, Aug 28 (Reuters) – Austrian biotech firm Intercell <ICEL.VI> said on Thursday its partner Merck & Co <MRK.N> has started a Phase II clinical trial to evaluate a vaccine candidate against Staphylococcus aureus infections.
Merck is responsible for clinical development, manufacturing and marketing of the vaccine. Intercell is eligible to receive milestone payments and royalties on future net sales
This is the second trial start following a separate Phase II trial launch in December 2007. Read more
Filed under: CDC Watch, Vaccine Science, Vaccine/Disease Analysis
Parents have questions about the risk-benefit equation of the Hepatitis B vaccine. It is possible for a parent to be quite certain that their infant is not at risk of prenatal or birth exposure to this disease. The risk factors for exposure during infancy, early childhood, and the elementary school years can be reasonably well assessed on an individual basis. Read more